Novartis Asks 4th Circ. To Block $1M Aredia, Zometa Verdict

Law360, New York (June 12, 2012, 3:10 PM EDT) -- Seeking to undo a $1.2 million verdict related to bone drugs Aredia and Zometa, Novartis Pharmaceuticals Corp. told the Fourth Circuit on Friday that a lower court erred when deciding what evidence to allow in a case that’s part of vast multidistrict litigation.

A North Carolina judge awarded the damages two years ago after jurors found the company failed to warn a woman's doctor the medicines could cause a severe jaw disease known as osteonecrosis.

Novartis contends a new trial is warranted because of various alleged...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.